These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35961186)

  • 1. Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities.
    Kim S; Kim K
    Biomater Adv; 2022 Sep; 140():213059. PubMed ID: 35961186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomaterial-Mediated Exogenous Facile Coating of Natural Killer Cells for Enhancing Anticancer Efficacy toward Hepatocellular Carcinoma.
    Jangid AK; Kim S; Kim HJ; Kim K
    Bioconjug Chem; 2023 Oct; 34(10):1789-1801. PubMed ID: 37726892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface Engineering of Natural Killer Cells with CD44-targeting Ligands for Augmented Cancer Immunotherapy.
    Kim S; Li S; Jangid AK; Park HW; Lee DJ; Jung HS; Kim K
    Small; 2024 Jun; 20(24):e2306738. PubMed ID: 38161257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailoring tumor-recognizable hyaluronic acid-lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells.
    Lee CE; Kim S; Park HW; Lee W; Jangid AK; Choi Y; Jeong WJ; Kim K
    Nano Converg; 2023 Dec; 10(1):56. PubMed ID: 38097911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research progress in leveraging biomaterials for enhancing NK cell immunotherapy.
    Tang Y; Qian C
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 52(3):267-278. PubMed ID: 37476938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Design of Hyaluronic Acid-Lipid Conjugate Biomaterial for Augmenting CD44 Recognition of Surface-Engineered NK Cells.
    Park HW; Lee W; Kim S; Jangid AK; Park J; Lee CE; Kim K
    Biomacromolecules; 2024 Mar; 25(3):1959-1971. PubMed ID: 38379131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells.
    Diwanji N; Getts D; Wang Y
    Immunohorizons; 2024 Jan; 8(1):97-105. PubMed ID: 38240638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
    Mantesso S; Geerts D; Spanholtz J; Kučerová L
    Front Immunol; 2020; 11():607131. PubMed ID: 33391277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Surface Decoration of Phenylboronic Acid onto Natural Killer Cells for Sialic Acid-Mediated Versatile Cancer Cell Targeting.
    Jangid AK; Kim S; Park HW; Kim HJ; Kim K
    Biomacromolecules; 2024 Jan; 25(1):222-237. PubMed ID: 38130077
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Park HW; Lee CE; Kim S; Jeong WJ; Kim K
    Tissue Eng Part B Rev; 2024 Jun; 30(3):327-339. PubMed ID: 37830185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells.
    Han B; Song Y; Park J; Doh J
    J Control Release; 2022 Mar; 343():379-391. PubMed ID: 35124129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonviral genome engineering of natural killer cells.
    Robbins GM; Wang M; Pomeroy EJ; Moriarity BS
    Stem Cell Res Ther; 2021 Jun; 12(1):350. PubMed ID: 34134774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.